Overview

Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer. Patients should have previously received an anthracycline and a taxane. The safety of this treatment will also be studied.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
R-Pharm
Treatments:
Capecitabine
Epothilones
Criteria
- Patients must have received prior treatment which included both an anthracycline
(i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).

- Patients must have received no more than two prior chemotherapy regimens. Patients who
have not received treatment for metastatic disease must have relapsed within one year.

- Patients may not have any history of brain and/or leptomeningeal metastases.

- Patients may not have Grade 2 or worse neuropathy at the time of study entry.

- Patients may not have had prior treatment with any epothilones and/or capecitabine
(i.e. Xeloda)